By staff writers

October 18, 2019 -- Ortho Clinical Diagnostics has announced the U.S. Food and Drug Administration (FDA) clearance of its Ortho Sera ID-Micro Typing System (MTS) extended antigen phenotyping in blood transfusion products, for use on the company's Ortho Vision analyzer.

Phenotyping is done prior to blood transfusions to determine if patients have antibodies to various blood group antigens; extended phenotyping is performed when patients may have developed atypical antibodies. According to the company, Ortho Sera covers more than 99% of the most commonly tested antigens. Extended phenotyping is completed in an automated fashion on one platform, with results available in 20 minutes, the company noted in a statement.

Blood centers claim FDA safety rules threaten patient access
The U.S. Food and Drug Administration (FDA) should continue to assess the effects of new guidance for controlling the risk of bacterial contamination...
Ortho appoints new CEO
Ortho Clinical Diagnostics, a Carlyle Group company, announced that Robert Yates is stepping down from the post of CEO and medical device chief executive...
AACC preview: A rough guide to diagnostics on show
Bruce Carlson, longtime diagnostic market analyst and publisher of Kalorama Information, takes you on a trip through this year's product offerings at...
Ortho's Vitros BNP assay gets CE Mark
Ortho Clinical Diagnostics' Vitros N-terminal pro b-type natriuretic peptide (NT-proBNP) assay for diagnosing and assessing risk for cardiovascular events,...
Ortho gets CE Mark for Vitros troponin I assay
Ortho Clinical Diagnostics has received the CE Mark for Vitros, the company's high-sensitivity troponin I assay for detecting signs of heart attack.

Copyright © 2019

Last Updated np 10/29/2019 10:34:38 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.